ACMT Position Statement: Position on the Recent Judicial Challenge of U.S. Food and Drug Administration Approval of Mifepristone.
作者信息
Mazer-Amirshahi Maryann, Stolbach Andrew I, Ye Peggy
机构信息
Georgetown University School of Medicine, Washington, DC, USA.
Department of Emergency Medicine, MedStar Washington Hospital Center, Washington, DC, USA.
出版信息
J Med Toxicol. 2023 Oct;19(4):414-415. doi: 10.1007/s13181-023-00960-4. Epub 2023 Aug 7.
Abstract
摘要
相似文献
1
ACMT Position Statement: Position on the Recent Judicial Challenge of U.S. Food and Drug Administration Approval of Mifepristone.美国毒理学会立场声明：关于近期美国食品药品监督管理局批准米非司酮面临司法挑战的立场
J Med Toxicol. 2023 Oct;19(4):414-415. doi: 10.1007/s13181-023-00960-4. Epub 2023 Aug 7.
2
Update on medication abortion.药物流产的最新情况。
J Midwifery Womens Health. 2007 Jan-Feb;52(1):23-30. doi: 10.1016/j.jmwh.2006.10.006.
3
Mifepristone: less obvious adverse effects.
Ann Pharmacother. 2001 Mar;35(3):381-2. doi: 10.1345/aph.10410.
4
Mifepristone Paternalism at the FDA.FDA 的米非司酮家长主义。
J Law Med Ethics. 2023;51(3):554-559. doi: 10.1017/jme.2023.98. Epub 2023 Dec 13.
5
The Mifepristone Litigation: Untangling the Implications of the Fifth Circuit's Decision for Abortion Access and the U.S. Food and Drug Administration.米非司酮诉讼案：厘清第五巡回法院裁决对堕胎准入和美国食品药品监督管理局的影响。
Ann Intern Med. 2023 Dec;176(12):1666-1669. doi: 10.7326/M23-2431. Epub 2023 Nov 7.
6
The Mifepristone Case and the Legitimacy of the FDA.米非司酮案与美国食品药品监督管理局的合法性
JAMA. 2023 Jun 27;329(24):2121-2122. doi: 10.1001/jama.2023.8712.
7
The next two decades of mifepristone at FDA: History as destiny.米非司酮在 FDA 的未来二十年：历史即命运。
Contraception. 2022 May;109:1-7. doi: 10.1016/j.contraception.2022.01.016. Epub 2022 Feb 4.
8
Abortion pill gets FDA approval.
Circulation. 2000 Oct 10;102(15):E9030-1.
9
Mifepristone approval delayed, supporters look to action by FDA.米非司酮的批准被推迟，支持者期待美国食品药品监督管理局采取行动。
Contracept Technol Update. 2000 May;21(5):53-5.
10
FDA puts restrictions on use of controversial diabetes drug.美国食品药品监督管理局对有争议的糖尿病药物的使用加以限制。
Mayo Clin Womens Healthsource. 2011 Feb;15(2):3.
本文引用的文献
1
Toxicity of abortifacients: A review for physicians in the post roe era.流产药物的毒性：罗伊诉韦德案判决后医生需要了解的知识。
Am J Emerg Med. 2022 Nov;61:7-11. doi: 10.1016/j.ajem.2022.08.027. Epub 2022 Aug 18.
2
Abortion Safety and Use with Normally Prescribed Mifepristone in Canada.加拿大正常处方米非司酮的安全性和使用
N Engl J Med. 2022 Jan 6;386(1):57-67. doi: 10.1056/NEJMsa2109779. Epub 2021 Dec 8.
Zotero 插件